Loading...
AstraZeneca PLC
AZNCF•PNK
Healthcare
Drug Manufacturers - General
$147.50
$0.11(0.07%)
AstraZeneca PLC (AZNCF) Financial Performance & Income Statement Overview
Review AstraZeneca PLC’s income statement, balance sheet, and cash flow reports with annual and quarterly breakdowns.
Revenue Growth
18.03%
↑ 18.03%
Operating Income Growth
22.09%
↑ 22.09%
Net Income Growth
18.14%
↑ 18.14%
Operating Cash Flow Growth
14.65%
↑ 14.65%
Operating Margin
19.38%
↑ 19.38%
Gross Margin
79.64%
↑ 79.64%
Net Profit Margin
14.26%
↑ 14.26%
ROE
19.37%
↑ 19.37%
ROIC
13.82%
↑ 13.82%
AstraZeneca PLC (AZNCF) Income Statement & Financial Overview
Review AstraZeneca PLC's (AZNCF) income statement with detailed quarterly and annual figures.
| Metric | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 |
|---|---|---|---|---|
| Revenue | $13.59B | $14.89B | $13.56B | $12.94B |
| Cost of Revenue | $2.23B | $2.73B | $3.08B | $2.18B |
| Gross Profit | $11.36B | $12.17B | $10.48B | $10.76B |
| Gross Profit Ratio | $0.84 | $0.82 | $0.77 | $0.83 |
| R&D Expenses | $3.16B | $4.68B | $3.12B | $3.008B |
| SG&A Expenses | $4.57B | $5.55B | $5.29B | $5.06B |
| Operating Expenses | $7.68B | $10.13B | $8.38B | $8.009B |
| Total Costs & Expenses | $9.91B | $12.86B | $11.46B | $10.19B |
| Interest Income | $84.00M | $64.00M | $183.00M | $100.00M |
| Interest Expense | $349.00M | $429.00M | $457.00M | $443.00M |
| Depreciation & Amortization | $1.28B | $2.34B | $1.82B | $1.28B |
| EBITDA | $5.08B | $4.43B | $4.10B | $4.12B |
| EBITDA Ratio | $0.37 | $0.30 | $0.30 | $0.32 |
| Operating Income | $3.67B | $2.04B | $2.11B | $2.75B |
| Operating Income Ratio | $0.27 | $0.14 | $0.16 | $0.21 |
| Other Income/Expenses (Net) | -$272.00M | -$370.00M | -$278.00M | -$349.00M |
| Income Before Tax | $3.40B | $1.67B | $1.83B | $2.40B |
| Income Before Tax Ratio | $0.25 | $0.11 | $0.13 | $0.19 |
| Income Tax Expense | $481.00M | $166.00M | $395.00M | $469.00M |
| Net Income | $2.92B | $1.50B | $1.43B | $1.93B |
| Net Income Ratio | $0.21 | $0.10 | $0.11 | $0.15 |
| EPS | $1.88 | $0.97 | $0.92 | $1.24 |
| Diluted EPS | $1.87 | $0.96 | $0.92 | $1.24 |
| Weighted Avg Shares Outstanding | $1.55B | $1.55B | $1.55B | $1.55B |
| Weighted Avg Shares Outstanding (Diluted) | $1.56B | $1.56B | $1.56B | $1.56B |
Unlock 25+ Years of Financial Data
Get access to extended historical data, advanced metrics, and more with our premium plan